New Clinical Trials Regulations Guidelines
The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 represent the most significant overhaul of UK clinical trials regulation in two decades. Signed into law on 11 April 2025, these regulations take full effect from 28 April 2026, following a 12-month implementation period designed to help sponsors prepare for the changes.
The legislation will make clinical trial approval processes more flexible and efficient, allowing the UK to reduce CTA approval timelines.
Extensive guidance has been published by the MHRA and HRA (links are provided within and also at the end of this article). This article summarises the key points contained within the guidances (current as of the latest updates on 12-Jan-26).
Key Updates
- Combined Review Process – formalised with additional guidance provided
- Accelerated Timelines – significantly faster assessment times introduced
- Notifiable Trials – expedited approval timelines for certain clinical studies
- Modification Updates – recategorisation of modifications (previously amendments)
- Lapse of trial approval – approvals lapse after 24 months for trials with no recruitment
- Transparency and accountability – enhanced transparency obligations and archiving and retention requirements
- Labelling – updated labelling requirements
- Non-Investigational Medicinal Products (NIMPs) – now defined with specific requirements
- Safety Reporting and Pharmacovigilance – updates to safety reporting requirements
- Participant Protection and Consent – introduction of inclusion and diversity plans and simplified consent requirements for certain studies
- International Standards and Guideline Alignment – UK specific annotations to ICH E6 (R3) and clarifications to the Declaration of Helsinki standards
Next Steps – Strategic Implementation
Early adopters who proactively implement these changes will gain significant competitive advantages through faster study startup, reduced regulatory burden and enhanced operational efficiency.
Sponsors should already have begun implementation planning and if not, should start immediately, focusing on systems, training, stakeholder engagement, and pathway evaluation. The comprehensive nature of these changes requires systematic preparation to the maximise benefits.
For long-term success, organisations should view these changes as enablers of innovation rather than regulatory requirements. Leverage the flexibility, gain efficiencies, apply the integrated pathways to advance scientific objectives whilst still maintaining exemplary standards of scientific integrity.
The 2025 amendments represent more than regulatory change – they constitute a fundamental reimagining of how clinical research can be conducted efficiently, ethically, innovatively, and strategically.
This is an opportunity to strengthen your competitive position through thoughtful preparation and strategic implementation.
Further information on these updates can be found in a more detailed article here.
Join our award-winning Fusion Pharma team (recognised for excellence in communications for our Windsor Framework webinar campaign) on 10 March 2026 as we explore these important changes and how best to prepare for their implementation. Register your webinar attendance here.
Further Information
MHRA Clinical Trials Hub: Latest guidance and updates
HRA Guidance on Changes to Clinical Trials Regulations
HRA Clinical Trials Regulations Reform
HRA Research Transparency Strategy
Legislation.gov.uk: Full text of the amended regulations
Fusion can provide expert assistance with the understanding, planning, implementation and necessary upskilling of relevant teams (including a comprehensive SOP update programme) to help prepare sponsors for these significant updates. Speak to our team today to ensure your organisation is ready.
While the information in this article is considered to be true and correct at the date of publication, changes in guidance and/or experience may impact on the accuracy of the information. Please refer to the relevant guidance for the latest information.
